Fig. 2.

Relationship between SCZ symptoms and CGm BOLD signal power. We extracted average CGm power for each patient with available symptom ratings (n = 153). (A) Significant positive relationship between CGm power and symptom ratings in SCZ (r = 0.18, P < 0.03), verified using Spearman’s ρ given somewhat nonnormally distributed data (ρ = 0.2, P < 0.015). (B and C) Results held across SCZ samples, increasing confidence in the effect (i.e., joint probability of independent effects P < 0.002, marked in blue boxes). All identified relationships held when examining Gm variance (SI Appendix, Fig. S4). Notably, all effects were no longer significant after GSR, suggesting GS carries clinically meaningful information. The shaded area marks the 95% confidence interval around the best-fit line.